Italy simplifies over-the-counter generics price and reimbursement

Home/Policies & Legislation | Posted 26/03/2021 post-comment0 Post your comment

The Italian Drugs and Medicines Agency (Agenzia Italiana del Farmaco, AIFA) has simplified its price and reimbursement procedure for class C generic/biosimilar medicines. As of February 2021, generic/biosimilar versions of over-the-counter class C reference products will automatically be classified as class C products.

28 MD002360

The details of this simplified procedure were first announced in December 2020 [1].
It does not apply to generic/hybrid/biosimilar medicines that include any additional therapeutic indications compared with the reference medicinal product. This also removes the need for negotiations with the Health Technology Assessment (HTA) Department and with AIFA’s Technical Scientific advisory Committee (CTS) and the Price and Reimbursement Committee (CPR).

The new simplified approach applies to products with package interchangeability with reference products. Here, the packages have the same quantity of active ingredient, pharmaceutical form, route of administration, methods of release and dosage units, which leads to automatic inclusion in class C for reimbursement purposes. However, any generic/hybrid/biosimilar medicines featuring packages differing in strength, pharmaceutical form, number of dosage units and methods of release, from those of the reference medicinal product, are designated to class ‘C Non-Negotiated’ (C(nn)) and cannot be automatically included in class C.

Related articles
Infliximab biosimilars for IBD patients experience from Italy

AIFA updates the Transparency Lists for generics

Biosimilars policies in Italy


To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.



Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

1. GaBI Online - Generics and Biosimilars Initiative. Italy publishes new guidelines on pricing and reimbursement of generics and biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Mar 26]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
PDUFA VI: FDA could promote generics competition
47 MD001813
Home/Policies & Legislation Posted 29/07/2022
House bill passes FDA funding fees but conflicts with Senate bill
User Fee V13H23
Home/Policies & Legislation Posted 15/07/2022
US Senate clarifies status of interchangeable biosimilar exclusivity
Interchangeability V18K30
Home/Policies & Legislation Posted 27/05/2022
Nomenclature of biologicals and biosimilars in Peru
02 AA010638
Home/Policies & Legislation Posted 20/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010